Akebia Therapeutics received a rating change following an upward trend in its earnings estimates, which institutional investors use for valuation.
3 reports, 3 independent
Updated Tue 00:00
No new developments lately
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Akebia Therapeutics received a rating change following an upward trend in its earnings estimates, which institutional investors use for valuation.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Leerink downgraded Akebia Therapeutics while Wall Street Zen upgraded its shares.1 source
Akebia Therapeutics received a rating change due to upward earnings estimates.1 source
Keep exploring
The entities involved
-
Akebia Therapeutics (United States)
company in Cambridge, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- dailypolitical.com
- themarketsdaily.com
- ZacksAkebia Therapeutics (AKBA) Upgraded to Strong Buy: Here's What You Should Know Akebia Therapeutics (AKBA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Stro